Medication Safety of Elderly Patients in Hospital and Ambulatory Setting

RWTH Aachen University61 enrolled

Overview

The purpose of this study is to determine whether additional pharmaceutical care for elderly patients (home-cared patients, nursing-home residents) has a positive impact on drug-related readmissions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Elderly Pharmaceutical Care Hospital Readmission Health Services for the Aged Medication Safety

Interventions

Pharmaceutical Care ServiceOTHER

Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patient 65 years old or older * patient admitted to one of the project wards * minimum hospitalization: 3 days * written informed consent (patient or the legal representative) * current medication of the patient at hospitalization Exclusion Criteria: * patients included in this study previously

Locations (1)

University Hospital Aachen

Aachen, Germany

Outcomes

Primary Outcomes

Drug-related readmission

Time frame: one year after discharge from the cooperating ward

Secondary Outcomes

Adverse drug events

Time frame: during hospital stay on cooperating wards(continuous data collection during routine ward rounds;hence,duration of data collection is dependent on individual hospital stay of each patient, up to 1 year) and 1 year after discharge from the cooperating ward

Number of prescribed potentially inappropriate medication (PRISCUS-criteria)

The PRISCUS list was developed in 2010 for the German market. Potentially inappropriate medications were judged as inappropriate by an expert panel using the Delphi technique. \[Holt et al., Dtsch Arztebl 2010\]

time to readmission

Time frame: one year after discharge from the cooperating ward

Number of accepted recommendations in the intervention group

Time frame: during hospital stay on cooperating wards (continuous data collection during routine ward rounds; hence, duration of data collection is dependent on individual hospital stay of each patient, up to one year) in the intervention group

time for intervention

time recording for pharmaceutical care service

Time frame: during hospital stay on cooperating wards (continuous data collection during routine ward rounds; hence, duration of data collection is dependent on individual hospital stay of each patient, up to one year) in the intervention group

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.